Search
Nelipepimut-S
go.drugbank.com/drugs/DB06226InvestigationalSynonyms: HER-2/NEU PEPTIDE (369-377), Human receptor tyrosine-protein kinase erbB-2 (proto-oncogene Neu, tyrosine kinase-type cell surface receptor HER2, CD340)-(347-355)-peptideCategories: Receptor Protein-Tyrosine Kinases, Receptor, Epidermal Growth FactorPamidronic acid
go.drugbank.com/drugs/DB00282ApprovedInvestigationalPamidronic acid is a second generation, nitrogen containing bisphosphonate similar to neridronic acid and alendronic acid. Pamidronic acid was first described in the literature in 1977. The second generation bisphosphonates are less comm...
Categories: Drugs for Treatment of Bone DiseasesProducts: Pamidronate Disodium for Injection, Pamitor 15 mg/ml - Konzentrat zur Herstellung einer InfusionslösungCandesartan cilexetil
go.drugbank.com/drugs/DB00796ApprovedInvestigationalIt may also be used as an alternative agent for the treatment of heart failure, systolic dysfunction, myocardial infarction and coronary artery disease. … Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension.
Mixtures: Mar-candesartan / Hctz, Mar-candesartan / HctzCategories: Antihypertensive Agents Indicated for Hypertension, P-glycoprotein inhibitorsAfoxolaner
go.drugbank.com/drugs/DB11369ExperimentalVet approvedMixtures: Nexgard Spectra 38mg/8mg Chewable Tablets for Dogs >7.5-15kg, Nexgard Spectra 9mg/2mg Chewable Tablets for Dogs 2-3.5kgProducts: NexGard 11mg chewable tablets for dogs 2-4kg, NexGard 136mg chewable tablets for dogs > 25-50kgSacituzumab govitecan
go.drugbank.com/drugs/DB12893ApprovedInvestigational[A193653] Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment. … Metastatic triple-negative breast cancer (mTNBC) is an aggressive form of breast cancer with limited treatment options involving cytotoxic chemotherapy agents.
Tislelizumab
go.drugbank.com/drugs/DB14922ApprovedInvestigationalTislelizumab is a humanized monoclonal IgG4 antibody against programmed death receptor-1 (PD-1). … This approval was based on positive results demonstrated in the RATIONALE 302 study, where an 8.6-month median overall survival rate was observed for tislelizumab treatment compared to 6.3-month for chemotherapy
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitorsMonoamine Oxidase-A Deficiency (MAO-A)
smpdb.ca/view/SMP0125595DiseaseThe buildup of chemicals may also damage the brain, leading to a lower IQ in individuals with this disorder. … MAO-A is an enzyme that catalyzes the deamination of amines such as epinephrine, dopamine and tyramine, as part of the tyrosine metabolism pathway.
Drugs: Pyridoxal phosphate · Ademetionine · Ascorbic acid · Aspartic acid · Tyrosine · Glutamic acid +20 moreSphingolipid Signaling (Receptor)
smpdb.ca/view/SMP0524344SignalingThrough these receptor‑specific G protein couplings—spanning cAMP suppression, Ca²⁺ mobilization, PKC activation, Rho GTPase–driven cytoskeletal remodeling, and PI3K/Akt and MAPK pathways—S1P orchestrates
Enzymes: Sphingosine 1-phosphate receptor 2, Sphingosine 1-phosphate receptor 4Monoamine Oxidase-A Deficiency (MAO-A)
smpdb.ca/view/SMP0000533DiseaseThe buildup of chemicals may also damage the brain, leading to a lower IQ in individuals with this disorder. … MAO-A is an enzyme that catalyzes the deamination of amines such as epinephrine, dopamine and tyramine, as part of the tyrosine metabolism pathway.
Drugs: Pyridoxal phosphate · Ademetionine · Ascorbic acid · Aspartic acid · Tyrosine · Glutamic acid +20 moreSystemic Embolism
go.drugbank.com/conditions/DBCOND0077405